Novartis AG
NVSEF
$106.50
-$3.64-3.30%
OTC PK
03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
---|---|---|---|---|---|
Net Income | -15.65% | -19.59% | 124.64% | 111.49% | 116.98% |
Total Depreciation and Amortization | 62.14% | 47.56% | -63.39% | -60.05% | -55.91% |
Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
Total Other Non-Cash Items | 396.33% | 519.40% | -131.38% | -123.22% | -128.38% |
Change in Net Operating Assets | 36.33% | 4.73% | -122.17% | -29.02% | -78.99% |
Cash from Operations | 38.01% | 21.86% | -0.31% | -1.95% | -11.44% |
Capital Expenditure | -24.49% | -28.87% | -26.46% | -25.43% | -35.31% |
Sale of Property, Plant, and Equipment | -56.82% | -63.71% | 16.00% | 75.69% | 53.85% |
Cash Acquisitions | 0.40% | -12.83% | -1.15% | -6,136.61% | -19,857.89% |
Divestitures | 740.91% | 3,466.67% | -- | -1,166.67% | 4.35% |
Other Investing Activities | -11.48% | -123.27% | -115.37% | -100.90% | -135.10% |
Cash from Investing | -6.08% | -234.26% | -205.96% | -160.74% | -317.47% |
Total Debt Issued | 310.19% | 411.84% | 4,403.55% | 2,540.61% | 129.35% |
Total Debt Repaid | -30.14% | -1.09% | 6.54% | -65.69% | -23.18% |
Issuance of Common Stock | -- | -81.13% | -81.13% | -84.28% | -- |
Repurchase of Common Stock | -43.40% | 4.50% | 32.73% | 50.21% | 36.91% |
Issuance of Preferred Stock | -- | -- | -- | -- | -- |
Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
Total Dividends Paid | -48.84% | -5.09% | -5.09% | -5.09% | 28.23% |
Other Financing Activities | -104.78% | -105.95% | -101.18% | 4,961.11% | 3,950.00% |
Cash from Financing | -47.71% | 17.76% | 47.05% | 54.55% | 49.40% |
Foreign Exchange rate Adjustments | 106.02% | -398.00% | 117.28% | -199.40% | -214.66% |
Miscellaneous Cash Flow Adjustments | -- | -- | 200.00% | -- | -- |
Net Change in Cash | 5.06% | -132.91% | -67.27% | -141.07% | -36.66% |